接受羟钴胺治疗患者的高铁血红蛋白水平升高:病例系列与体外分析
该研究为单中心回顾性病例系列(2011年1月1日至2019年4月30日)联合体外分析,纳入27例接受5 g或10 g羟钴胺(OHCbl)治疗的患者。结果显示6例(22.2%)发生高铁血红蛋白血症,均在5 g OHCbl给药后出现,中位峰值7.1%(IQR 2.2-16.4%),中位出现时间11.4小时;2例接受亚甲蓝治疗均无效,死亡17例(63%)。体外实验中OHCbl呈剂量依赖性升高总血红蛋白,但未检测到MetHb升高。作者认为高铁血红蛋白血症与OHCbl给药存在时间关联,并非CO-血氧计伪影,对已缺氧或携氧能力受损患者可能有重要影响。
要点
- 27例接受羟钴胺治疗者中6例(22.2%)发生高铁血红蛋白血症,均在5 g剂量后出现,中位峰值7.1%(IQR 2.2-16.4%)。
- 高铁血红蛋白中位出现时间为给药后11.4小时,临床需在用药后数小时至十余小时监测MetHb。
- 2例高铁血红蛋白血症患者接受亚甲蓝治疗均无效。
- 体外实验中羟钴胺呈剂量依赖性升高总血红蛋白,但未检测到MetHb升高。
- 作者认为该时间关联并非CO-血氧计伪影,对已缺氧或一氧化碳血红蛋白升高的患者可能有严重影响。
适用人群与场景
- 2011年1月1日至2019年4月30日期间单中心接受5 g或10 g羟钴胺(OHCbl)治疗的患者。
- 21例(77.8%)因火灾或烟雾吸入接受OHCbl,2例因与火灾烟雾无关的病因不明严重酸中毒接受OHCbl。
处置流程与药物剂量
- 病例系列中5例(18.5%)接受10 g OHCbl,其余接受5 g OHCbl。
- 发生高铁血红蛋白血症的2例患者接受了亚甲蓝(MB)治疗,均无效。
红旗征与不能漏的情况
- 已缺氧或一氧化碳血红蛋白升高导致携氧能力受损的患者,接受OHCbl后出现高铁血红蛋白血症可能有严重影响。
- 接受5 g OHCbl后出现高铁血红蛋白血症,中位峰值7.1%(IQR 2.2-16.4%),中位时间11.4小时。
研究设计与关键结果
- 研究类型:单中心回顾性病例系列联合体外分析;病例系列纳入27例接受5 g或10 g OHCbl的患者,中位年龄53岁(IQR 38-64),20例(74.1%)为男性。
- 6例(22.2%)发生高铁血红蛋白血症,均在5 g OHCbl给药后出现;其中4例暴露于火灾和烟雾,2例因与火灾烟雾无关的病因不明严重酸中毒用药。
- 高铁血红蛋白中位峰值7.1%(IQR 2.2-16.4%),中位出现时间给药后11.4小时;2例接受亚甲蓝治疗均无效;死亡17例(63%)。
- 体外研究:将废弃血液分为全血和血浆样本,加入OHCbl和生理盐水达到0×、1×、2×、4×峰值治疗浓度,在给药后0、2、4小时分析;观察到总血红蛋白呈剂量依赖性升高,但未检测到MetHb升高。
证据类型、等级与局限
- 证据类型:单中心回顾性病例系列联合体外分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为高铁血红蛋白血症的形成与羟钴胺给药之间存在值得注意的时间关联,且似乎并非CO-血氧计伪影。
- 作者认为这对已缺氧或一氧化碳血红蛋白导致携氧能力受损的患者可能有深远影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Historically, the first step in treating cyanide (CN-) toxicity utilized antidotes to induce methemoglobinemia. This is concerning in patients who are already hypoxemic or have elevated carboxyhemoglobin. Hydroxocobalamin (OHCbl) is now the first-line antidote for CN- toxicity and is not known to induce methemoglobinemia. We observed elevated methemoglobin (MetHb) levels in several patients treated with OHCbl and sought to investigate the incidence of MetHb formation following administration of OHCbl.
METHODS: Chart review: A single-center, retrospective case series of patients who received 5 or 10 g of hydroxocobalamin from 01/01/2011 through 04/30/2019. Data was analyzed using descriptive statistics. In-vitro study: Discarded blood was separated into whole blood and plasma samples. OHCbl and normal saline was added to reach 0×, 1×, 2×, and 4× peak therapeutic concentrations and analyzed at times 0, 2, and 4 h after administration.
RESULTS: Chart review: Twenty-seven cases of OHCbl administration were identified. The median age was 53 years (IQR 38 - 64) and 20 (74.1%) were male. Exposure to a house fire or smoke inhalation was the reason for OHCbl administration in 21 (77.8%) patients. Five (18.5%) patients received 10 g of OHCbl while the rest received 5 g. Six (22.2%) patients developed methemoglobinemia, all after 5 g OHCbl administration; four had been exposed to fire and smoke, two received the medication for severe acidosis of unknown etiology not related to fire or smoke. The median peak level was 7.1% (IQR 2.2 - 16.4%) at a median time of 11.4 h post-administration. Two patients received methylene blue (MB), neither responded. Death occurred in 17 (63%) cases. In-vitro study: We observed a dose dependent elevation in total hemoglobin but did not detect any increase in MetHb.
CONCLUSION: We observed a noteworthy temporal association between the formation of methemoglobinemia and the administration of hydroxocobalamin. This does not appear to be an artifact of the CO-oximeters. This could have profound implications for patients who are already hypoxemic or have impaired oxygen carrying capacity from carboxyhemoglobin.
参考来源
- Kiernan EA, Carpenter JE, Dunkley CA, et al. Elevated methemoglobin levels in patients treated with hydroxocobalamin: a case series and in-vitro analysis. Clin Toxicol (Phila). 2022. PMID: 35549585. doi:10.1080/15563650.2022.2072315
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。